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ttp://dx.doi.org/10.1016/j.ajpath.2014.06.024miR-17-92 is an oncogenic miRNA cluster implicated in the development of several cancers; however, it
remains unknown whether the miR-17-92 cluster is able to regulate cholangiocarcinogenesis. This
study was designed to investigate the biological functions and molecular mechanisms of the miR-17-92
cluster in cholangiocarcinoma. In situ hybridization and quantitative RT-PCR analysis showed that the
miR-17-92 cluster is highly expressed in human cholangiocarcinoma cells compared with the
nonneoplastic biliary epithelial cells. Forced overexpression of the miR-17-92 cluster or its members,
miR-92a and miR-19a, in cultured human cholangiocarcinoma cells enhanced tumor cell proliferation,
colony formation, and invasiveness, in vitro. Overexpression of the miR-17-92 cluster or miR-92a also
enhanced cholangiocarcinoma growth in vivo in hairless outbred mice with severe combined immu-
nodeﬁciency (SHO-PrkdcscidHrhr). The tumor-suppressor, phosphatase and tensin homolog deleted on
chromosome 10 (PTEN), was identiﬁed as a bona ﬁde target of both miR-92a and miR-19a in chol-
angiocarcinoma cells via sequence prediction, 30 untranslated region luciferase activity assay, and
Western blot analysis. Accordingly, overexpression of the PTEN open reading frame protein (devoid of 30
untranslated region) prevented miR-92ae or miR-19aeinduced cholangiocarcinoma cell growth.
Microarray analysis revealed additional targets of the miR-17-92 cluster in human cholangiocarcinoma
cells, including APAF-1 and PRDM2. Moreover, we observed that the expression of the miR-17-92 cluster
is regulated by IL-6/Stat3, a key oncogenic signaling pathway pivotal in cholangiocarcinogenesis.
Taken together, our ﬁndings disclose a novel IL-6/Stat3emiR-17-92 clusterePTEN signaling axis that
is crucial for cholangiocarcinogenesis and tumor progression. (Am J Pathol 2014, 184: 2828e2839;
http://dx.doi.org/10.1016/j.ajpath.2014.06.024)Supported by NIH grants CA102325, CA106280, CA134568, and
DK077776 (T.W.).
Disclosures: None declared.miRNAs are a class of small (usually 19 to 24 nucleotides
long) noncoding RNAs that globally regulate gene expres-
sion through targeting mRNA degradation or translational
repression.1 They are known to target mRNAs through
complementary binding at 30 untranslated regions (UTRs)
with their seed sequences (usually two to seven nucleo-
tides).2,3 Studies in recent years have shown that miRNAs
have diverse biological and pathophysiological functions,
including regulation of carcinogenesis.4,5 Although many
miRNAs share sequence homology and are grouped into
different families, approximately half of human miRNA
genes are clustered together.6e8 The miR-17-92 cluster is one
of the cluster miRNAs and has been identiﬁed as an oncogene
(alias Oncomir-1).9 The miR-17-92 gene (located at the openstigative Pathology.
.reading frame of human chromosome 13, C13orf25) is
expressed as a polycistronic primary transcript containing six
tandem stem-loop hairpin structures that ultimately yield six
mature miRNAs (miR-17, miR-18, miR-19a, miR-20, miR-
19b, and miR-92a). miR-17-92 has been identiﬁed as an
oncogenic miRNA cluster implicated in several cancers,10e16
including hepatocellular carcinoma.17 However, it remains
unknown whether the miR-17-92 cluster is involved in
cholangiocarcinoma, a highly malignant cancer of the biliary
epithelia.
miR-17-92 Cluster and CholangiocarcinomaCholangiocarcinoma comprises approximately 10% to
15% of hepatobiliary neoplasms, and its incidence and
mortality are increasing.18e22 The tumor is among the
most difﬁcult forms of cancer to treat and generally has a
poor prognosis. Most cases are diagnosed at a late stage
when lymph node or distant metastasis has occurred and
the disease is refractory to treatment. The pathogenesis of
cholangiocarcinoma involves activation of growth-
promoting signaling pathways and disruption of tumor-
suppressor genes. Notably, activation of IL-6/Stat3
signaling and loss of functional phosphatase and
tensin homolog deleted on chromosome 10 (PTEN) are
among the documented key alterations implicated in
cholangiocarcinogenesis.
IL-6 is a classic biliary mitogen that has been shown to
increase the growth and survival of biliary epithelial cells
and cholangiocarcinoma cells. It mediates actions through
binding to gp130 receptor, resulting in phosphorylation and
activation of Stat3. Compelling experimental evidences
have established a pivotal role of IL-6/Stat3 signaling in
cholangiocarcinoma biological features.23e29 Notably, the
serum level of IL-6 in patients with cholangiocarcinoma is
signiﬁcantly elevated, and its level correlates with tumor
burden or response to therapy.30e32
PTEN is a key tumor-suppressor gene that is dis-
rupted or suppressed in various cancers,33e36 including
cholangiocarcinoma.37 Although a progressive reduction
of PTEN is frequently associated with more aggressive
cancers, subtle variations in PTEN levels are recognized
to have critical consequences for tumor progression.34,36
Whereas mutations of PTEN have not been reported in
cholangiocarcinomas, loss of functional PTEN has been
implicated in cholangiocarcinogenesis.37,38 In a murine
model of intrahepatic cholangiocarcinoma, disruption of
the PTEN gene was associated with development of
cholangiocarcinoma.37 Consistent with the observations
that loss of PTEN protein is a prognostic factor in other
malignancies, loss of PTEN expression in patients
with cholangiocarcinoma has been linked to more
aggressive tumor growth parameters and worse survival
outcome.38
In the current study, we provide the ﬁrst evidence that the
miR-17-92 cluster is highly expressed in cholangiocarcinoma
compared with nontumorous biliary epithelial cells. We show
that miR-92a is the most abundant miRNA of the miR-17-92
cluster in cholangiocarcinoma. Overexpression of the
miR-17-92 cluster or miR-92a enhanced human chol-
angiocarcinoma cell proliferation, colony formation, and
invasiveness in vitro and enhanced tumor growth in mice.
PTEN was identiﬁed as a bona ﬁde target of both miR-92a
and miR-19a in cholangiocarcinoma cells. Furthermore, we
observed that IL-6/Stat3 enhances the expression of the miR-
17-92 cluster in cholangiocarcinoma cells. Our ﬁndings
suggest a novel interaction among IL-6/Stat3, miR-17-92
cluster, and PTEN signaling pathways in human chol-
angiocarcinoma cells.The American Journal of Pathology - ajp.amjpathol.orgMaterials and Methods
Materials
Dulbecco’s modiﬁed minimum essential medium and heat-
inactivated fetal bovine serum (FBS) were purchased from
Sigma (St. Louis, MO). OPTI-MEMereduced serum me-
dium, RPMI 1640 medium, Lipofectamine 2000 reagent,
and puromycin were purchased from Invitrogen (Carlsbad,
CA). Bronchial Epithelial Cell Basal Medium, with sup-
plemental growth factors in BEGM SingleQuot Kit, was
purchased from Lonza (Walkersville, MD). The miR-19a,
miR-92a, or miR-17-92 cluster expressed and scrambled
control lentiviral particles with enhanced green ﬂuorescent
protein were obtained from GeneCopoeia (Rockville, MD).
Dulbecco’s Phosphate-Buffered Saline Solution was pur-
chased from Thermo Scientiﬁc (Logan, UT). Protease in-
hibitor cocktail and protein phosphatase inhibitor were
purchased from Roche (Mannheim, Germany). The Stat3
inhibitor V (Stattic) was purchased from Calbiochem
(Darmstadt, Germany). The JAK inhibitors AZD1480 and
INCB18424 were purchased from ChemieTek (Indian-
apolis, IN). Mouse monoclonal antieb-actin antibody was
from Sigma; rabbit anti-PTEN and antiephospho-Stat3
antibodies were from Cell Signaling (Danvers, MA).
Cell Culture
Four human cholangiocarcinoma cell lines, including CCLP1,
SG231, HuCCT1, and TFK1, and one immortalized noncan-
cerous human cholangiocyte cell line (H69) were used.
HuCCT1 and TFK1 cells were obtained from the Japanese
Cancer Research Resources Bank (Ibaraki City, Japan); H69
cells were kindly provided by Dr. Gregory J. Gores (Mayo
Clinic College of Medicine, Rochester, MN). The CCLP1
cells were cultured in Dulbecco’s modiﬁed minimum essential
medium containing 10% FBS, SG231 cells were cultured in
OPTI-MEM medium containing 5% FBS, and TFK1 and
HuCCT1 cells were cultured in RPMI 1640 medium con-
taining 10%FBS. TheH69 cells were cultured in BEBMBasal
Medium supplemented with growth factors (BEGM Single-
Quot Kit) and 10% FBS. All cells were cultured in a humid-
iﬁed atmosphere of 5% CO2 incubator at 37C. The miR-19a,
miR-92a, or miR-17-92 clustereoverexpressed and scramble
control stable cell lines were established by transduction with
the corresponding lentiviral vector or miRNA-scrambled
control lentiviral vector, followed by selection with media
containing puromycin.
In Situ Hybridization for miRNA
In situ hybridization for miR-92a was performed in the
formalin-ﬁxed, parafﬁn-embedded tissue specimens surgi-
cally resected from patients diagnosed with chol-
angiocarcinoma by using the MiRCURY LNA microRNA
ISH Optimization Kit (Exiqon, Vedbaek, Denmark) with the2829
Zhu et alapproval of the Institutional Review Board. Brieﬂy, parafﬁn
sections (6-mm thick) were deparafﬁnized and treated with
15 mg/mL proteinase-K at 37C for 10 minutes. After
dehydration, slides were incubated with 100 nmol/L miR-
92a locked nucleic acid probe (50-DIG-ACAGGCCGG-
GACAAGTGCAATA-30-DIG) at 50C for 2 hours. This
was followed by stringent washes with 5 standard saline
citrate, 1 saline sodium citrate, and 0.2 saline sodium
citrate buffers at 50C; DIG blocking reagent (Roche,
Mannheim, Germany) in maleic acid buffer containing 2%
sheep serum at room temperature for 15 minutes; and
alkaline phosphataseeconjugated anti-digoxigenin (diluted
1:500 in blocking reagent; Roche) at room temperature for 2
hours. Enzymatic development was performed by incu-
bating the slides with 4-nitro-blue tetrazolium and 5-brom-
4-chloro-30-indolylphosphate substrate (Roche) at 30C for
2 hours to allow formation of dark-blue 4-nitro-blue tetra-
zolium formazan precipitate, followed by nuclear fast red
counterstain (Vector Laboratories, Burlingame, CA) at room
temperature for 10 minutes. Slides were then dismantled in
water, dehydrated in alcohol solutions, and mounted with
mounting medium (Vector Laboratories). Scrambled probe
and U6 small nuclear RNAespeciﬁc probe were used as
system control. A standard 4-point scale method was used to
evaluate the staining intensity under microscope and the
results were scored as follows: 0 (negative), 1 (þ), 2 (þþ),
or 3 (þþþ), according to established criteria.39 Speciﬁcally,
3 (þþþ) indicates dark staining that is easily visible with a
low-power objective and involves >50% of cells; 2 (þþ),
moderate darkly staining areas and <50% of cells; 1 (þ),
weak or pale staining in any proportion of cells not easily
seen under a low power; and 0 (negative), no staining
(showing none of the above staining). The same procedure
was used to analyze the cholangiocarcinoma tissue arrays
(obtained from BioCat GmbH, Heidelberg, Germany; 44
cases of cholangiocarcinoma and 4 cases of nonneoplastic
tissues).
Quantitative RT-PCR
Cellular total RNA was isolated using TRIzol reagent (Invi-
trogen). Reverse transcription was performed by using an
miScript Reverse Transcription Kit (Qiagen, Valencia, CA).
miScript SYBR Green PCR Kit (Qiagen) and miScript Primer
Assays for six different miRNAs were used to amplify indi-
vidual mature forms of miR-17/18/19a/19b/20/92a on a
C1000 Thermal Cycler (Bio-Rad, Hercules, CA). U6 small
nuclear 2 (U6b) was used as the internal control. For quanti-
tation of PTEN mRNA levels, reverse transcription was per-
formed by using the SuperscriptTM II Reverse Transcriptase
Kit (Invitrogen). Then, the PTEN gene was ampliﬁed by using
the QuantiFast SYBR Green PCR Kit (Qiagen). Glyceralde-
hyde-3-phosphate dehydrogenase (GAPDH) was used as the
internal control. The GAPDH (Hs_GAPDH_1_SG), PTEN
(Hs_PTEN_1_SG), APAF1 (Hs_APAF1_1_SG), and PRDM2
(Hs_PRDM2_1_SG) QuantiTect primers were from Qiagen.2830The preemiR-17-92 cluster forward primer is 50-CAG-
TAAAGGTAAGGAGAGCTCAATCTG-30, and the reverse
primer is 50-CATACAACCACTAAGCTAAAGAATAATC-
TGA-30. miRNA and mRNA expression levels were normal-
ized to their corresponding internal control genes, and relative
change was calculated using the 2DDCT method.
Cell Proliferation WST-1 Assay
The growth of human cholangiocarcinoma cells was
measured by using the WST-1 reagent from Roche (Indi-
anapolis, IN). Brieﬂy, 2  103 cells were seeded onto each
well of 96-well plates and cultured for 24 hours to allow
attachment. Then, the medium was replaced with fresh
medium containing 1% FBS or speciﬁc reagents, as indi-
cated, and the cultures were continued for the indicated
days. For cell growth measurement, WST-1 reagent was
added to each well and the cells were incubated at 37C and
5% CO2 for 1 hour; absorbance at 450 nm was measured
using an ELISA plate reader.
Colony-Formation Assay
Cells (1  103) were cultured in 10-cm dishes for 14 days to
allow colony formation. Colonies were ﬁxed in 100%
methanol and stained with 0.1% crystal violet solution
(Amersco, Solon, OH) for counting.
Cell Invasion Assay
The cell invasion assay was performed in Matrigel-coated
transwell chambers (BD Biosciences Discovery Labware,
Bedford, MA). A cell suspension (500 mL; 5  104 cells/
mL) was added to each of the upper chambers. Cell culture
medium containing 10% FBS was added to each of the
lower chambers as chemoattractant. After incubating cells at
37C for 24 hours, the cells on the upper surface of the
membrane were removed with a cotton swab. The invading
cells on the lower surface of the membrane were ﬁxed in
100% methanol and stained with Mayer’s hematoxylin so-
lution (IHC World, Woodstock, MD). Then, the invading
cells were counted under a microscope, and for each
chamber, eight ﬁelds were randomly selected for counting.
Western Blot Analysis
The logarithmically growing cells were washed twice with
ice-cold phosphate-buffered saline (PBS), scraped off the
plates with 1 mL PBS with 100 nmol/L phenyl-
methylsulfonyl ﬂuoride, and centrifuged. The cells were then
incubated in a lysis buffer containing 50 mmol/L HEPES and
1 mmol/L EDTA (pH 8.0); one tablet of protease inhibitor
cocktail (Roche) and one tablet of phosphatase inhibitors
(Roche) were added per 10-mL buffer. After sonication on
ice, the cell lysates were centrifuged at 12,000  g for 10
minutes at 4C, and the supernatants were collected forajp.amjpathol.org - The American Journal of Pathology
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measured with the Bio-Rad Protein Assay Kit (Bio-Rad,
Hercules, CA). After boiling for 5 minutes in the protein
loading buffer with 2-mercaptoethanol, the samples were
separated on Any kD Mini-PROTEAN TGX Gel (Bio-Rad)
and then transferred onto the nitrocellulose membrane (Bio-
Rad). The membranes were blocked in PBS with 0.1%
Tween 20 (PBS-T) containing 5% nonfat milk for 1 hour at
room temperature. Blots were incubated with different pri-
mary antibodies (at appropriate dilutions) in PBS-T contain-
ing 5% nonfat milk at 4C overnight. After three washes with
PBS-T, the membranes were incubated with IRDye second-
ary antibody (Licor, Lincoln, NE) at 1:10,000 dilutions in
PBS-T containing 5% nonfat milk for 1 hour. After three
washes with PBS-T, signals were visualized and the relative
densities of protein bands were quantiﬁed and normalized to
actin using the ODYSSEY Infrared Imaging System (Licor).
miRNA, Anti-miRNA, siRNA, and Plasmid Transfection
siRNA targeting Stat3, GP130, or scrambled control
(Ambion, Grand Island, NY), miR-19a mimic or miR-
19aespeciﬁc anti-miRNA (Qiagen), pcDNA3 control, or
pcDNA3-PTEN orf plasmid (Addgene, Cambridge, MA)
was transfected into cells by using Lipofectamine 2000
(Invitrogen), as per the manufacturer’s instruction. After
transfection at indicated time periods, cells were analyzed
for proliferation and the cell lysates were obtained for
Western blot analysis.
IL-6 and Inhibitor Treatment
Recombinant human IL-6 (R&D Systems, Minneapolis,
MN) was prepared according to the product’s manual, dis-
solved in sterile PBS containing 0.1% bovine serum albu-
min. Stattic, AZD1480, or INCB18424 was dissolved in
dimethyl sulfoxide at 10 mmol/L. Serum was withdrawn 24
hours before IL-6 and/or inhibitor treatment to synchronize
cells.
DNA Pull-Down Assay
Cells were lysed by sonication in HKMG buffer containing
10 mmol/L HEPES (pH 7.9), 100 mmol/L KCl, 5 mmol/L
MgCl2, 10% glycerol, 1 mmol/L dithiothreitol, and 0.5% NP-
40 with protease inhibitor cocktail and phosphatase inhibitors
for the preparation of nuclear extract. The obtained nuclear
extracts were precleared with streptavidin-agarose resin
(Thermo Scientiﬁc) for 1 hour. The precleared samples were
then incubated with 1 mg biotinylated double-stranded
oligonucleotide STAT3-binding site (50-biotin-GTTTCTGA-
GAATTCCGGAATTTCCTGAACCAC-30 and 50-biotin-
GTGGTTCAGGAAATTCCGGAATTCTCAGAAAC-30;
synthesized by Integrated DNA Technologies, Coralville, IA)
and 10 mg poly(dI-dC) at 4C for overnight. DNA-protein
complex was collected by incubation with streptavidin-The American Journal of Pathology - ajp.amjpathol.orgagarose resin on a shaker to prevent precipitation at 4C for
1 hour. The resin-bound complex was washed at least 5
with 1.0 mL HKMG buffer, followed by centrifugation at
2000  g for 1 to 2 minutes to discard the supernatant. After
the resin-bound complex was boiled in SDS-PAGE sample
loading buffer, the released protein was loaded onto Any kD
Mini-PROTEAN TGX Gel (Bio-Rad) and identiﬁed by using
Western blot analysis with speciﬁc antibodies.
Chromatin Immunoprecipitation
The assay was performed by using a Simplechip Enzymatic
Chromatin IP kit (Cell Signaling Technology, Billerica,
MA), according to the manufacturer’s instructions. Immu-
noprecipitation was performed by using 5 mg of antie
phospho-STAT3 antibody; rabbit IgG antibody was used as
a negative control. Chromatin immunoprecipitation primers
were designed to amplify the STAT3 binding region in the
miR-17-92 cluster promoter. The primers are as follows: 50-
GGGCATTAAAGACATCCTTTGG-30 and 50-GAGCAC-
CTCCTTCTTCACATT-30.
Luciferase Reporter Activity Assay
Cells were seeded in 12-well plates and cultured overnight
to allow attachment. The cells were then cotransfected with
miRNA mimic or Allstar negative control siRNA (Qiagen)
and 0.1 mg per well of pEZX-MT01-PTEN 30UTR Renilla/
ﬁreﬂy dual-luciferase reporter plasmid (GeneCopoeia). The
cell lysates were obtained 24 hours after transfection, and
luciferase activity was measured in a Centro XS3 LB 960
Microplate Fluorescence Reader (Berthold Technologies,
Oak Ridge, TN) by using the Dual-Luciferase reporter assay
system (Promega, Madison, WI). The Renilla luciferase
activity was used as internal control, and the ratio of Fireﬂy/
Renilla activity was calculated for normalization.
mRNA Microarray Analysis
Total RNA from miR-17-92 clustereoverexpressed or con-
trol CCLP1 cells were used forWhole Human Genome Oligo
Microarray (performed by Arraystar, Rockville, MD).
Brieﬂy, total RNA from each sample was ampliﬁed and
transcribed into ﬂuorescent cRNA using the manufacturer’s
Agilent’s Quick Amp Labeling protocol, version 5.7 (Agilent
Technologies, Santa Clara, CA). The labeled cRNAs were
hybridized onto the Whole Human Genome Oligo Micro-
array (4 44K; Agilent Technologies). After having washed
the slides, the arrays were scanned by the Agilent Scanner
G2505B (Agilent Technologies). Agilent Feature Extraction
software version 11.0.1.1 (Agilent Technologies) was used to
analyze acquired array images. Quantile normalization and
subsequent data processing were performed using the
GeneSpring GX software version 11.5.1 (Agilent Technol-
ogies). Raw data of detected genes were normalized
for further analysis. Differentially expressed genes were2831
Zhu et alidentiﬁed through fold change ﬁltering. The data were
deposited into Gene Expression Omnibus (http://www.ncbi.
nlm.nih.gov/geo; accession number GSE58060).
SCID Mice Tumor Xenograft Studies
Four-week-old male severe combined immunodeﬁciency
(SCID) hairless outbred (SHO) mice (Crl:SHO-PrkdcscidHrhr,
strain 474) were purchased from Charles River (Wilmington,
MA). Two complementary xenograft models (s.c. and ortho-
topic) were used. For the s.c. xenograft model, 3  106 miR-
92ae or miR-17-92 clustereoverexpressed or control CCLP1
cells were inoculated into the ﬂanks of mice (six mice per2832group), and the mice were observed over 4 weeks for tumor
formation. The tumor volume was measured weekly with a
caliper and calculated by using the following formula:
larger diameter  ðsmaller diameterÞ2=2:On sacriﬁce, the
tumorswere recovered and thewet weights of each tumorwere
determined. A portion of each tumor was selected for H&E
staining,Western blot analysis, and quantitative RT-PCR (RT-
qPCR) analysis. For the orthotopic transplant model, 3 107/
mL miR-17-92 clustereoverexpressed or control CCLP1 cell
suspension was mixed with Corning Matrigel Basement
Membrane Matrix High Concentration (Corning, NY) in a 1:1
ratio; a 50-mL ﬁnal volume (containing 7.5  105 cells) was
injected directly into the liver of mice in surgery under local
anesthesia. Themice were sacriﬁced 6 weeks after intrahepatic
inoculation to document tumor growth.
Statistical Analysis
Results are presented as means  SD or SEM from a
minimum of three replicates. Differences between groups
were compared using either Student’s t-test or one-way
analysis of variance. P < 0.05 was considered statistically
signiﬁcant. The analysis was performed using SPSS statis-
tical software version 19.0 (IBM, Armonk, NY). For data
from human samples, statistical signiﬁcance between means
was determined by the nonparametric Kruskal-Wallis test.
Results
Expression of miR-92a Is Increased in Human
Cholangiocarcinoma Tissues and Cell Lines
ThemiR-17-92 cluster is a polycistronic primary transcript and
yields six mature miRNAs: miR-17, miR-18a, miR-19a, miR-
20a, miR-19b, and miR-92a (Figure 1A). To determine theFigure 1 High expression of the miR-17-92 cluster in human chol-
angiocarcinoma tissues and cell lines. A: Genomic structure of the miR-
17-92 cluster. The miR-17-92 cluster is polycistronic, and located at
C13orf25. The preemiR-17-92 cluster is cleaved, generating six mature
miRNAs (miR-17, miR-18, miR-19a, miR-20, miR-19b, and miR-92).
B: Expression of the miR-17-92 cluster in cholangiocarcinoma cell lines.
RT-qPCR for mature miRNA in the miR-17-92 cluster in a human trans-
formed cholangiocyte cell line (H69) and four human cholangiocarcinoma
cell lines (CCLP1, HuCCT1, SG231, and TFK1). Total cellular RNA was
extracted for RT-qPCR (n Z 3). The expression level of each individual
miRNA is normalized to RNU6B (internal control). All of the six miRNAs
(miR-17/18/19a/19b/20/92) are highly expressed in four chol-
angiocarcinoma cell lines (CCLP-1, HuCCT1, SG231, and TFK-1 cells)
compared with the noncancerous control cell line H69. Among the six
mature miRNAs, miR-92a is the most abundant, followed by miR-17 and
miR-20. C: In situ hybridization for mature miR-92a in human chol-
angiocarcinoma tissues. Representative in situ hybridization images de-
pict the expression of miR-92a in human cholangiocarcinoma tissues.
Note positive miR-92a staining in cholangiocarcinoma cells and negative
staining in normal bile duct epithelial cells (positive signals are in dark
blue; nuclei were counterstained in red). D: Distribution of miR-92a
staining intensity scores in human cholangiocarcinoma tissue arrays
(N Z 44). *P < 0.05 (Kruskal-Wallis nonparameter test).
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levels by RT-qPCR analyses in human cholangiocarcinoma
cells and noncancerous human biliary epithelial cells. Higher
levels of miR-92a, miR-20, and miR-17 expression were
observed in all four human cholangiocarcinoma cell linesThe American Journal of Pathology - ajp.amjpathol.org(CCLP1, HuCCT1, SG231, and TFK1) when compared with
the noncancerous human biliary epithelial cell line (H69)
(Figure 1B). The expression levels of miR-18, miR-19a, and
miR-19b were also increased in cholangiocarcinoma cells
(noticeably increased in SG231 cells and slightly increased in
HuCCT1, CCLP1, and TFK1 cells). miR-92a is the highest
among all of the six miRNAs of the cluster in all four human
cholangiocarcinoma cell lines.
Given that miR-92a is the most abundant miRNA among
the miR-17-92 cluster in human cholangiocarcinoma cell
lines, we performed in situ hybridization using locked nucleic
acidemodiﬁed probe against miR-92a in human chol-
angiocarcinoma tissue samples and nonneoplastic bile duct
epithelia. Formalin-ﬁxed, parafﬁn-embedded tumor and liver
tissues from 12 patients who underwent surgical resections for
cholangiocarcinoma and 41 cases of cholangiocarcinoma tis-
sue arrays were analyzed. We observed that miR-92a is highly
expressed in 12 (100%) of 12 cases of archived chol-
angiocarcinoma tissues, which is in contrast to the weak or
absent staining in nonneoplastic bile duct and peribiliary
glands (Figure 1C). For cholangiocarcinoma tissue array
analysis, the staining frequency and intensity of miR-92a are
also signiﬁcantly higher in cholangiocarcinoma cells (63.41%
þþþ, 19.51%þþ, 12.20%þ, and 4.88%) compared with
the nonneoplastic bile duct epithelial cells (0.0% þþþ, 0.0%
þþ, 66.67% þ, and 33.33% ; P Z 0.04) (Figure 1D and
Supplemental Table S1). These ﬁndings document increased
expression of the miR-17-92 cluster, particularly miR-92a, in
human cholangiocarcinoma tissues and cell lines.Figure 2 miR-92a overexpression promotes cholangiocarcinoma cell
growth in vitro and in vivo. AeC: miR-92a overexpression promotes chol-
angiocarcinoma cell growth, colony formation, and cell invasion in vitro.
Human cholangiocarcinoma cells (CCLP1) were infected with miR-92a
lentivirus and miRNA scrambled control lentivirus, respectively. The sta-
bly transduced cells were analyzed for proliferation, colonogenic potential,
and invasion ability, as described in Materials and Methods. A: miR-92a
overexpression promotes cholangiocarcinoma cell growth. Cell growth
curves of human cholangiocarcinoma cells (CCLP1) stably transduced with
miR-92a lentivirus (indicated as LV-miR-92a) or scrambled control (indi-
cated as LV-control). miR-92a levels were measured by RT-qPCR. B: miR-92a
overexpression enhances cholangiocarcinoma cell colony formation. The
numbers of colonies were counted after 14 days. Representative images
showing colonies formed in cell culture dishes. Average colony formation
efﬁciency is shown. C: miR-92a overexpression promotes chol-
angiocarcinoma cell invasion. Representative images showing migrated cell
staining by hematoxylin. Average numbers of the invaded cells are shown.
DeG: miR-92a promotes cholangiocarcinoma growth in vivo. miR-
92aeoverexpressed or scrambled control CCLP1 cells (1.0  108) were
inoculated s.c. into ﬂank areas of SCID hairless mice (nZ 6), and the mice
were closely monitored for tumor growth. Thirty days after inoculation, the
mice were sacriﬁced and the tumors were recovered. D: Photographs of
xenograft tumor masses from SCID mice highlight that miR-92a promotes
tumor growth. Images are of the mice and the xenograft tumors that were
recovered. E: miR-92a overexpression signiﬁcantly increases xenograft
tumor volume. F: miR-92a signiﬁcantly increases the weight of the xeno-
graft tumors. G: Western blot analysis reveals decreased PTEN protein levels
in xenograft tumor tissues by miR-92a. Data are presented as means  SEM
(AeC) or means SD (E and F). NZ 3 (AeC); NZ 6 (E and F). *P < 0.05,
**P < 0.01, and ***P < 0.001.
2833
Zhu et almiR-92a Enhances Cholangiocarcinoma Cell Growth,
in Vitro and in Vivo
To investigate the role of miR-92a in cholangiocarcinoma
cell growth, we constructed human cholangiocarcinoma cell
lines with stable overexpression of miR-92a by infecting the
parental cell line (CCLP1) with lentivirus particles carrying
the miR-92a gene (this vector also carries the enhanced
green ﬂuorescent protein gene under the control of the same
promoter). High infection efﬁciency was conﬁrmed by the
expression of enhanced green ﬂuorescent protein in nearly
all transduced cells. Successful overexpression of miR-92a2834in miR-92a lentivirus stably transduced cells was veriﬁed by
RT-qPCR (cells transduced with lentivirus carrying scram-
bled control miRNA were used as control). Overexpression
of miR-92a signiﬁcantly increased the growth of chol-
angiocarcinoma cells in vitro (Figure 2A). miR-92a over-
expression also increased colony-formation efﬁciency and
enhanced cell invasion (Figure 2, B and C). These ﬁndings
demonstrate that miR-92a increases the malignant potential
of cholangiocarcinoma cells in vitro.
To determine the effect of miR-92a on cholangiocarcinoma
growth in vivo, we inoculated miR-92aeoverexpressed and
scrambled control CCLP1 cells into the ﬂanks of SCID hairless
outbred mice (SHO-PrkdcscidHrhr). Although only three of six
mice inoculated with scrambled control cells showed visible
tumors, six of sixmice inoculatedwithmiR-92a overexpression
cells developed visible tumors 30 days after inoculation
(Figure 2D). The scrambled control tumors were smaller
(P < 0.05) and lower in weight compared with the miR-
92aeoverexpressed tumors (Figure 2, D and E). An approxi-
mately sixfold increase in tumor weight was observed in
miR-92aeoverexpressed tumors compared with the controls
(0.19  0.04 g versus 0.02  0.01 g; PZ 0.014) (Figure 2F).
Western blot analysis of the tumor tissues showed reduction of
PTEN protein in miR-92aeoverexpressed tumors (Figure 2G).miR-17-92 Cluster Increases Cholangiocarcinoma Cell
Growth, in Vitro and in Vivo
Given that miR-92a is able to increase cholangiocarcinoma
cell growth, as shown above, we sought to further evaluateFigure 3 Overexpression of miR-17-92 cluster promotes cholangio-
carcinoma cell growth in vitro and in vivo. The miR-17-92 cluster promotes
human cholangiocarcinoma cell proliferation (A), colony formation (B), and cell
invasion (C) in vitro. Human cholangiocarcinoma cells (CCLP1) were infected
with miR-17-92 cluster lentivirus and miRNA scrambled control lentivirus,
respectively, and the stable cells were analyzed for proliferation, colonogenic
potential, and invasion ability, as described in Materials and Methods. A: Cell
proliferation assay (WST-1). Cell growth curves of human cholangiocarcinoma
cells (CCLP1) stably transduced with miR-17-92 cluster lentivirus (indicated as
LV-miR-17-92) or scrambled control LV-control. ThemiR-17-92 cluster promotes
cell growth in cholangiocarcinoma cell lines. PreemiR-17-92 cluster levels were
measured by RT-qPCR. B: miR-17-92 cluster overexpression enhances chol-
angiocarcinoma cell colony formation. The numbers of colonies were counted
after 14 days. Representative images show colonies formed in cell culture
dishes. Average colony-forming efﬁciency is shown. C: miR-17-92 cluster
overexpression promotes cholangiocarcinoma cell invasion. Representative
images show migrated cell staining by hematoxylin. Average numbers of
invaded cells are shown. DeF: The miR-17-92 cluster promotes chol-
angiocarcinoma growth in vivo. miR-17-92 clustereoverexpressed or scrambled
control CCLP1 cells (1.0  108) were inoculated s.c. into ﬂank areas of SCID
hairless mice (nZ 6), and the mice were closely monitored for tumor growth.
Thirty days after inoculation, the mice were sacriﬁced and the tumors were
recovered. D: Photographs of xenograft tumor masses from SCIDmice show that
the miR-17-92 cluster promotes tumor growth. E: The volume of xenograft
tumors is signiﬁcantly increased by miR-17-92 cluster overexpression. F: The
weight of xenograft tumors is signiﬁcantly increased by miR-17-92 cluster
overexpression. Data are from four SCID mice (two mice died before 30 days).
Data represent means  SEM (AeC) or means  SD (E and F). NZ 3 (AeC);
NZ 4 to 6 (E); NZ 4 (F). *P < 0.05, **P < 0.01, and ***P < 0.001.
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Figure 4 miR-19a overexpression promotes cholangiocarcinoma cell
growth and colony formation in vitro. A: miR-19a overexpression promotes
cholangiocarcinoma cell growth. Cell growth curves of human chol-
angiocarcinoma cells (CCLP1) stably transduced with miR-19a lentivirus
(indicated as LV-miR-19a) or scrambled control (indicated as LV-control).
miR-19a levels were measured by RT-qPCR. B: miR-19a overexpression
promotes cholangiocarcinoma cell colony formation. The numbers of col-
onies were counted after 14 days. Representative images show colonies
formed in cell culture dishes. Average colony formation efﬁciency is shown.
C: miR-19a overexpression promotes cholangiocarcinoma cell invasion.
Representative images show migrated cell staining by hematoxylin. Average
numbers of invaded cells are shown. Data are presented as means  SEM.
N Z 3. *P < 0.05, ***P < 0.001.
miR-17-92 Cluster and Cholangiocarcinomathe effect of the miR-17-92 cluster by stably transducing
cholangiocarcinoma cells with lentivirus particles
expressing miR-17-92 cluster or the scrambled control
miRNA. Overexpression of the miR-17-92 cluster signif-
icantly increased the cholangiocarcinoma cell growth
in vitro (Figure 3A). miR-17-92 overexpression also
increased colony-formation efﬁciency and enhanced cell
invasion (Figure 3, B and C). When these cells were
inoculated s.c. into SCID hairless mice (SHO-
PrkdcscidHrhr), the miR-17-92 clustereoverexpressed cells
produced visible tumors 30 days after inoculation; in
contrast, the scrambled control cells failed to produce any
tumor under the same condition (Figure 3, DeF). When
these cells were transplanted orthotopically into the livers
of SCID hairless mice, the miR-17-92 clustereoverex-
pressed tumors exhibited larger tumor volume compared
with the scrambled control tumors (Supplemental
Figure S1). These ﬁndings provide in vitro and in vivo
evidences for a tumor-promoting effect of the miR-17-92
cluster in cholangiocarcinoma.
Because miR-19a is another member of the miR-17-92
cluster implicated in the growth regulation of other cancer
cells,40 we performed further experiments to determine
whether miR-19a might play a role in human chol-
angiocarcinoma cells. Overexpression of miR-19a enhanced
cholangiocarcinoma cell proliferation, colony formation,
and cell invasion (Figure 4A). Collectively, our ﬁndings
document an important oncogenic role of the miR-17-92
cluster and its members (including miR-92a and miR-19a)
in cholangiocarcinoma cell growth.
PTEN Is a Direct Target of miR-92a and miR-19a in
Cholangiocarcinoma Cells
In an effort to identify the potential targets that mediate miR-
17-92 actions in cholangiocarcinoma cells, we used the online
prediction tool Miranda (http://www.microrna.org/microrna,
last accessed October 12, 2013). This approach led to identi-
ﬁcation of PTEN as a key downstream target. Complementary
sequences of miR-92a and miR-19a were identiﬁed in the
30UTR of PTEN mRNA (Figure 5A). RT-qPCR and Western
blot analyses showed that overexpression of the miR-17-92
cluster or its members (miR-92a or miR-19a) led to reduc-
tion of PTEN mRNA and protein levels (Figure 5, B and C).
Treatment of human cholangiocarcinoma cells with miR-92a
or miR-19a mimic also reduced PTEN expression
(Figure 5C). Accordingly, miR-92a or miR-19a mimic treat-
ment decreased the PTEN 30UTR luciferase reporter activity
(Figure 5D). The role of PTEN in miR-92ae and miR-
19aeinduced cholangiocarcinoma cell growth was further
supported by the observation that forced overexpression of
PTEN open reading frame protein (without the 30UTR)
partially prevented miR-92ae and miR-19aeinduced tumor
cell growth (Figure 5E). These results demonstrate that PTEN
is a direct target of the miR-17-92 cluster through two of its
members, miR-92a and miR-19a.The American Journal of Pathology - ajp.amjpathol.orgTranscriptome and Sequence Analyses for Additional
Targets of miR-17-92 Cluster
To predict other targets of the miR-17-92 cluster, we per-
formed sequence analysis by using TargetScan (http://www.
targetscan.org, last accessed October 12, 2013), PicTar
(http://pictar.mdc-berlin.de, last accessed October 12,
2013), and Miranda. Such sequence analysis predicted
>30,000 targets that have at least one binding site for one or
multiple miRNAs in the miR-17-92 cluster. As a parallel
approach, we performed transcriptome analysis using
mRNA microarray and found that 2861 genes were down-
regulated in miR-17-92 clustereoverexpressed cells
compared with scrambled control cells (Supplemental
Figure S2A). There were 960 common genes identiﬁed by
both sequence prediction and transcription analysis.
PANTHER pathway analysis (http://www.pantherdb.org,
last accessed October 12, 2013) indicates that these common
genes are most enriched in Wnt, cadherin, and inﬂammation
pathways (Supplemental Table S2), which is consistent
with the molecular features of cholangiocarcinoma.41 By2835
Figure 5 miR-17-92 targets PTEN via miR-92a and miR-19a in cholangiocarcinoma cells. A: Predicted 8-mer and 7-mer-m8 binding sequence for miR-92a
and miR-19a in the 30UTR of PTEN mRNA. B: PTEN mRNA levels are decreased in miR-19a, miR-92a, or miR-17-92 clustereoverexpressed cells, as determined by
RT-qPCR analysis. C: PTEN protein levels are down-regulated in miR-19a, miR-92a, and miR-17-92 clustereoverexpressed stable cell lines, as determined by
using Western blot analysis. PTEN protein levels are also down-regulated by miR-19a mimic or miR-92a mimic in CCLP-1 cells. D: miR-92a or miR-19a mimic
signiﬁcantly reduces PTEN 30UTR luciferase activity. CCLP1 cells were transfected with miRNA mimic or scrambled control, together with PTEN 30UTR dual-
luciferase reporter plasmid. The luciferase activity was analyzed 24 hours after transfection. E: PTEN (ORF) overexpression inhibits the cell growth induced
by miR-19a or miR-92a. Data are presented as means  SEM (B and E) or means  SD (D). N Z 3 (B and D); N Z 6 (E). **P < 0.01, ***P < 0.001, and
****P < 0.0001.
Zhu et alcomparing the miR-17-92 clusteredown-regulated genes
with the online database of human tumor-suppressor gene,42
we found several highly possible targets, including APAF-
1 and PRDM2, in addition to PTEN, which are signiﬁ-
cantly down-regulated in miR-17-92 clustereoverexpressed
cholangiocarcinoma cells (Supplemental Table S3 and
Supplemental Figure S2B). These ﬁndings suggest that miR-
17-92eregulated cholangiocarcinoma growth may also
involve additional targets (including APAF-1 and PRDM2,
among others).
The Expression of miR-17-92 Cluster Is Up-Regulated
by IL-6/Stat3 Signaling
Given the noticeable up-regulation of miR-17-92 cluster in
cholangiocarcinoma cells, we sought to further explore the
mechanism that regulates miR-17-92 expression in chol-
angiocarcinoma cells. Because the promoter region of the
miR-17-92 cluster gene contains a conserved binding site for
Stat343,44 (Figure 6D), we postulated that activation of IL-6/
Stat3 signaling might be a potential mechanism for miR-17-
92 cluster up-regulation during cholangiocarcinogenesis.
Indeed, treatment of human cholangiocarcinoma cells with
IL-6 signiﬁcantly increased the expression of preemiR-17-
92 cluster mRNA (Figure 6A). IL-6 treatment also signiﬁ-
cantly increased the levels of each individual mature miRNA
of the miR-17-92 cluster (by 77- to 250-folds) (Supplemental
Figure S3). IL-6emediated induction of preemiR-17-92
cluster mRNA was almost completely abolished by siRNA
knockdown of Stat3 or GP130 (P < 0.01) (Figure 6B).
Similarly, pretreatment of human cholangiocarcinoma cells2836with 20 mmol/L Stat3 phosphorylation inhibitor Stattic45 or
20 mmol/L JAK inhibitor (AZD1480 or INCB18424) also
abolished IL-6einduced up-regulation of the miR-17-92
cluster (Figure 6, C and D). The DNA pull-down assay and
the chromatin immunoprecipitation assay showed that IL-6
treatment increased the association of phosphorylated Stat3
to its DNA binding site in miR-17-92 cluster gene promoter
(Figure 6, E and F). These ﬁndings suggest an important role
of IL-6/Stat3 signaling for up-regulation of the miR-17-92
cluster in human cholangiocarcinoma cells.
Discussion
The current study provides the ﬁrst evidence that the miR-17-
92 cluster is highly expressed in human cholangiocarcinoma
cells compared with the noncancerous human biliary
epithelial cells. Our data show that miR-92a is the most
abundant miRNA among the six mature miRNAs of the miR-
17-92 cluster in human cholangiocarcinoma. The role of the
miR-17-92 cluster in cholangiocarcinoma growth is estab-
lished by complementary in vitro and in vivo studies. We
observed that forced overexpression of the miR-17-92 cluster
or its members, miR-92a and miR-19a, in cultured human
cholangiocarcinoma cells enhanced tumor cell proliferation,
colony formation, and invasiveness in vitro. Overexpression
of the miR-17-92 cluster or miR-92a was also found to
enhance xenograft cholangiocarcinoma growth in mice.
These ﬁndings establish a key tumor-promoting role of the
miR-17-92 cluster in cholangiocarcinoma (Figure 7).
Our data show that PTEN is a direct target of the miR-17-
92 cluster through two of its members, miR-92a andajp.amjpathol.org - The American Journal of Pathology
Figure 7 Schematic illustration of the proposed mechanism for miR-17-
92 clustereinduced cholangiocarcinoma growth. The miR-17-92 cluster can
directly target PTEN via miR-19a and miR-92, which associate with 30UTR of
PTEN. Reduction of PTEN enhances cholangiocarcinoma cell proliferation
and invasion in vitro and tumor formation in vivo. Furthermore, IL-6 can up-
regulate the expression of miR-17-92 cluster through Stat3-mediated
transcription of the preemiR-17-92 cluster. CCA, cholangiocarcinoma.
Figure 6 IL-6 up-regulates miR-17-92 expression in cholangiocarcinoma cells through Stat3 activation. A: Stimulation of CCLP-1 cells with 20 ng/mL IL-6
increases the expression of the preemiR-17-92 cluster, as determined by RT-qPCR. B: IL-6emediated induction of the preemiR-17-92 cluster is abolished by
siRNA knockdown of Stat3 or the IL-6 receptor, GP130. RT-qPCR data are presented. C: IL-6emediated induction of the preemiR-17-92 cluster is abolished by
20 mmol/L Stat3 phosphorylation inhibitor Stattic. RT-qPCR data are presented. D: IL-6emediated induction of the preemiR-17-92 cluster is abrogated by 20
mmol/L JAK inhibitor, AZD1480 or INCB18424. RT-qPCR data are presented. E: IL-6 treatment increases binding of activated Stat3 to the promoter region of
the miR-17-92 cluster, as determined by biotinylated oligonucleotide precipitation assay. Stat3 binding sequence at promoter region of preemiR-17-92 was
biotinylated-linked and used to precipitate proteins after 20 ng/mL IL-6 treatment for 1 hour. Phospho-Stat3 protein was detected by using Western blot
analysis. F: Chromatin immunoprecipitation assay. The chromatin extracted from CCLP1 cells, treated with IL-6 or control vehicle, was subjected to immu-
noprecipitation with phospho-STAT3 antibody, and the precipitates were subjected to RT-qPCR analysis using primers to amplify the STAT3 binding region.
Normal rabbit IgG was used as the negative control. RT-qPCR data are presented. Data are presented as means  SEM (AeD and F). N Z 3 (AeD and F).
*P < 0.05, **P < 0.01, and ***P < 0.001.
miR-17-92 Cluster and CholangiocarcinomamiR-19a. This assertion is based on the following obser-
vations: i) complementary sequences of miR-92a and miR-
19a are present in the 30UTR of PTEN mRNA, ii) over-
expression of the miR-17-92 cluster or its members (miR-
92a or miR-19a) decreased PTEN mRNA and protein levels
in human cholangiocarcinoma cells, iii) treatment of human
cholangiocarcinoma cells with miR-92a or miR-19a reduced
PTEN protein expression, and iv) miR-92a or miR-19a
mimic treatment decreased PTEN 30UTR luciferase reporter
activity in human cholangiocarcinoma cells. Therefore, in-
hibition of PTEN may represent an important mechanism
for miR-17-92 clusteremediated cholangiocarcinoma
growth. The involvement of PTEN in miR-17-92einduced
cholangiocarcinoma cell growth is further supported by the
observation that overexpression of PTEN open reading
frame protein prevented miR-92ae or miR-19aeinduced
tumor cell growth.
In addition to PTEN, we observe that miR-17-92 cluster
also targets other proteins, including APAF-1 and PRDM2,
in human cholangiocarcinoma cells. It is possible that these
additional targets may also be implicated in miR-17-
92emediated cholangiocarcinoma growth.
Herein, we show that IL-6/Stat3 signaling transcriptionally
regulates the expression of the miR-17-92 cluster in chol-
angiocarcinoma cells. This assertion is based on the following
observations: i) a conserved Stat3 binding site is present in the
miR-17-92 cluster gene promoter, ii) IL-6 treatment increased
the levels of preemiR-17-92 and mature miRNAs of the miR-
17-92 cluster, iii) siRNA knockdown of Stat3 or GP130 or
inhibition of Stat3 phosphorylation abolished IL-6einduced
induction of the preemiR-17-92 cluster, and iv) IL-6 treatmentThe American Journal of Pathology - ajp.amjpathol.orgincreased the association of phosphorylated Stat3 to its DNA
binding site in the miR-17-92 cluster gene promoter. Thus,
activation of IL-6/Stat3 signaling may be an important factor
for induction ofmiR-17-92 expression in cholangiocarcinoma.2837
Zhu et alIn this context, it is notable that recent studies have shown that
miR-17-92 targets JAK-STAT pathway inhibitor SOCS3
(suppressors of cytokine signaling)46 and PIAS3 (protein
inhibitor of activated Stat3),47 two key negative regulators
of the JAK-STAT pathway. Thus, it is possible that the
IL-6/Stat3einduced miR-17-92 cluster may further amplify
IL-6/Stat3 signaling through targeting SOCS3 and PIAS3,
forming a positive feed-forward loop that drives carcinogen-
esis and tumor progression.
Cholangiocarcinoma is often difﬁcult to diagnose at an
early stage; accurate diagnosis frequently cannot be estab-
lished until the disease is advanced and often in the metastatic
stage, resulting in a poor prognosis. Given that the miR-17-
92 cluster, particularly miR-92a, is highly expressed in
cholangiocarcinoma, as shown in this study, further studies
are needed to validate whether the miR-17-92 cluster or
miR-92a can be used as a marker for early diagnosis of
cholangiocarcinoma. Moreover, in light of the key role of
miR-17-92 in cholangiocarcinogenesis and tumor progres-
sion, as described in the current study, further investigations
are warranted to determine whether miR-17-92 can be tar-
geted for the treatment of human cholangiocarcinoma.
Supplemental Data
Supplemental material for this article can be found at
http://dx.doi.org/10.1016/j.ajpath.2014.06.024.
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